Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05EKM
|
|||
| Former ID |
DIB002600
|
|||
| Drug Name |
FR-121196
|
|||
| Synonyms |
FR-121196; FR 121196; 133920-65-7; N-(4-Acetyl-1-piperazinyl)-4-fluorobenzenesulfonamide; PZQKOVUNWPDCCQ-UHFFFAOYSA-N; FR121196; ACMC-20mv5f; AC1L2ZLZ; SCHEMBL195526; CTK4B8875; DTXSID90158423; Piperazine, 1-acetyl-4-(((4-fluorophenyl)sulfonyl)amino)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Terminated | [1] | |
| Company |
Fujisawa Pharmaceutical Co Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C12H16FN3O3S
|
|||
| Canonical SMILES |
CC(=O)N1CCN(CC1)NS(=O)(=O)C2=CC=C(C=C2)F
|
|||
| InChI |
1S/C12H16FN3O3S/c1-10(17)15-6-8-16(9-7-15)14-20(18,19)12-4-2-11(13)3-5-12/h2-5,14H,6-9H2,1H3
|
|||
| InChIKey |
PZQKOVUNWPDCCQ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 133920-65-7
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Somatostatin receptor type 1 (SSTR1) | Target Info | Modulator | [2], [3] |
| Somatostatin receptor type 2 (SSTR2) | Target Info | Modulator | [4] | |
| Somatostatin receptor type 3 (SSTR3) | Target Info | Modulator | [2], [3] | |
| Somatostatin receptor type 4 (SSTR4) | Target Info | Modulator | [4] | |
| Somatostatin receptor type 5 (SSTR5) | Target Info | Modulator | [4] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| cAMP signaling pathway | ||||
| Gastric acid secretion | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Pathwhiz Pathway | Gastric Acid Production | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| SIDS Susceptibility Pathways | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001380) | |||
| REF 2 | Nat Rev Drug Discov. 2013 Feb;12(2):87-90. | |||
| REF 3 | Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation. Mol Endocrinol. 2010 Feb;24(2):436-46. | |||
| REF 4 | Role of somatostatin in the augmentation of hippocampal long-term potentiation by FR121196, a putative cognitive enhancer. Eur J Pharmacol. 1993 Sep 7;241(1):27-34. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.